Skip to main content

Table 2 Chromosomal aberrations in hepatocellular carcinoma (HCC) subgroups with a low (GE1) and high (GE2) proliferation gene expression profile

From: Gene networks and transcriptional regulators associated with liver cancer development and progression

Chr Arm Type of aberration Significanta HCC GE1 HCC GE2
GE1 GE2 Sizeb of intervals % cases affected Sizeb of intervals % cases affected
1 p Gain Yes 175 50 116 8.3
1 p Gain Loss No 885 30–50 885 33.3–41.7
1 q Gain Gain No 2214 50–80 2214 41.7–83.3
2 p/q Gain Gain No 92 50 92 33.3
3 p/q Gain Gain No 195 50–70 252 33.3–66.7
4 q Loss Yes 0 0 783 41.7– 50.0
5 p Loss Yes 0 0 106 41.7
5 q Gain Yes 207 50 207 8.8
5 q Gain Loss No 215 30–40 215 33.3
6 p Gain Gain No 474 50–60 474 58.3–75
6 q Gain Loss No 34 30 34 33.3
7 p/q Gain Yes 2111 40–70 915 8.3–25.0
7 q Gain Gain Yes 34 90 34 41.7
7 p/q Gain Gain No 298 60–90 298 33.3–58.3
8 p Loss Loss No 286 30–50 286 58.3–75
8 p Gain Loss No 55 30–50 28 41.7–50
8 q Gain Gain No 1364 50–100 1364 33.3–66.7
9 p Gain Gain No 34 50 34 33.3
9 q Gain Gain No 292 80 292 50
10 q Gain Gain No 16 60 16 41.7
11 p/q Gain Gain No 169 60–80 169 41.7–50
11 q Gain Gain Yes 400 100 400 50–58.3
12 p Gain Yes 85 60 85 16.7
12 q Gain Gain Yes 188 80 188 33.3
12 p/q Gain Gain No 213 50–80 213 33.3–50
13 q Loss Yes 568 10 1199 41.4–83.3
13 q Gain Yes 11 70 11 25
13 q Gain Gain No 10 70 10 33,3
14 q Gain Gain No 191 40–70 191 33.3–58.3
15 q Gain Gain No 43 50 43 58.3
16 p/q Gain Yes 721 50–60 706 8.3–16.7
16 p Gain Gain No 119 60 119 33.3–41.7
16 q Gain Loss Yes/no 157 50 157 33.3–50
17 p Gain Loss Yes/no 541 60–80 541 33.3–50
17 q Gain Gain No 1452 40–50 1452 41.5–75
18 q Loss Yes 149 10 149 58.3
18 q Loss Noc 668 10 668 50
19 p Gain Gain Yes 762 100 762 41.7–58.3
19 q Gain Gain Yes 39 70–90 39 16.7–41.7
19 q Gain Gain No 1030 80–90 1030 50
20 p/q Gain Gain No 841 30–60 841 50–66.7
21 q Loss Yes 0 0 91 41,7
21 q Gain Yes 43 70 43 25
22 q Gain Gain No 829 70–80 43 50
  1. The table only includes aberrations that spanned more than 10 probes. Similar aberrations found in both HCC subgroups were included when they affected > 50% cases in one tissue set and > 30% cases in the other; they are presented in italics. Aberrations that presented changes in the opposite direction in the HCC subgroups were included when the aberration incidence in each subgroup was ≥ 30%
  2. Chr chromosome
  3. aWe considered differential aberrations between the two HCC groups to be statistically significant when P < 0.05 in differential aberration analysis
  4. bThe interval size is expressed as the total number of probes that spanned the aberration interval
  5. cThe P value for differential loss of 18q in HCC-GE2 was 0.06